2024
Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial.
Cohen D, Goldberg J, Leichman L, Hochman T, Newman E, Du K, Megibow A, Oberstein P, Al-Rajabi R, Scott A, Bekaii-Saab T, Messersmith W, Weekes C. Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial. Journal Of Clinical Oncology 2024, 42: 4175-4175. DOI: 10.1200/jco.2024.42.16_suppl.4175.Peer-Reviewed Original ResearchR0 resection rateBR-PDACR0 resectionNeoadjuvant therapyR-PDACResection ratePancreatic adenocarcinomaOverall survivalResected tumorAdverse eventsImproved R0 resection ratesNon-hematological adverse eventsBorderline resectable pancreatic adenocarcinomaPhase 2 clinical trialBorderline resectable tumorsBR-PDAC patientsCentral radiology reviewLocalized pancreatic adenocarcinomaMulticenter open-labelCycles of gemcitabineResectable pancreatic adenocarcinomaStereotactic radiation therapyComplete surgical resectionHematologic AENab-paclitaxel
2021
Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848.
Tchelebi L, Winter K, Abrams RA, Safran H, Regine WF, McNulty S, Wu AJ, Du KL, Seaward SA, Bian SX, Aljumaily R, Shivnani AT, Moore T, Crocenzi T, DiPetrillo TA, Kuykendal A, Crane CH, Goodman KA. Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848. International Journal Of Radiation Oncology, Biology, Physics 2021, 111: S40. PMID: 34700550, DOI: 10.1016/j.ijrobp.2021.07.114.Peer-Reviewed Original ResearchInterprofessional Image Verification Workshop for Physician and Physics Residents: A Multi-Institutional Experience
Padilla L, Burmeister JW, Burnett OL, Covington EL, Den RB, Dominello MM, Du KL, Galavis PE, Junell S, Kahn J, Kishore M, Mooney K, Mukhopadhyay ND, Studenski MT, Yechieli RL, Fields EC. Interprofessional Image Verification Workshop for Physician and Physics Residents: A Multi-Institutional Experience. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: 1058-1065. PMID: 34380009, DOI: 10.1016/j.ijrobp.2021.07.1706.Peer-Reviewed Original ResearchBreaking Tradition to Bridge Bench and Bedside: Accelerating the MD-PhD-Residency Pathway.
Modrek AS, Tanese N, Placantonakis DG, Sulman EP, Rivera R, Du KL, Gerber NK, David G, Chesler M, Philips MR, Cangiarella J. Breaking Tradition to Bridge Bench and Bedside: Accelerating the MD-PhD-Residency Pathway. Academic Medicine 2021, 96: 518-521. PMID: 33464738, DOI: 10.1097/acm.0000000000003920.Peer-Reviewed Original Research
2020
Effects of M-CSF Inhibition And Radiotherapy In A Murine Model Of Colorectal Cancer
Nguy S, Diskin B, Adam S, Li E, Liria M, Domogauer J, Taneja S, Teruel J, Wang H, Osterman S, Miller G, Du K. Effects of M-CSF Inhibition And Radiotherapy In A Murine Model Of Colorectal Cancer. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e543-e544. DOI: 10.1016/j.ijrobp.2020.07.1694.Peer-Reviewed Original ResearchInterprofessional Image Verification Workshop for Physician and Physics Residents: A Multi-Institutional Experience
Padilla L, Burmeister J, Burnett O, Covington E, Den R, Dominello M, Du K, Galavis P, Junell S, Kahn J, Kishore M, Mooney K, Studenski M, Yechieli R, Fields E. Interprofessional Image Verification Workshop for Physician and Physics Residents: A Multi-Institutional Experience. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e433. DOI: 10.1016/j.ijrobp.2020.07.2517.Peer-Reviewed Original ResearchA Single Institution Review Of Efficacy Of Neoadjuvant Chemoradiation With Gemcitabine/Abraxane Compared to FOLFIRINOX in Pancreatic Ductal Adenocarcinoma
Nguy S, Du K. A Single Institution Review Of Efficacy Of Neoadjuvant Chemoradiation With Gemcitabine/Abraxane Compared to FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e658-e659. DOI: 10.1016/j.ijrobp.2020.07.1972.Peer-Reviewed Original ResearchA phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).
Wu J, Atkinson E, Leichman L, Patel H, Iqbal S, Du K, Bizekis C, Goldberg J, Thomas C, Cohen D, Becker D, Siolas D, Beri N, Oberstein P, Ku G. A phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC). Journal Of Clinical Oncology 2020, 38: 372-372. DOI: 10.1200/jco.2020.38.4_suppl.372.Peer-Reviewed Original ResearchEsophageal squamous cell carcinomaAdvanced esophageal squamous cell carcinomaClinical CRRadiation therapyPhase I/II studyCarboplatin/paclitaxelEfficacy of nivolumabGrade 2 esophagitisGrade 3/4 AEsGrade 5 toxicityOverall survival benefitPhase II portionSquamous cell carcinomaConcurrent chemoRTManageable toxicityLast dosePrimary endpointII studyUnacceptable toxicityElevated ASTSurvival benefitCell carcinomaChemoRTGrade 3Nivolumab
2019
Phase II multi-institutional study of nivolumab (Nivo), cabiralizumab (Cabira), and stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer (LAUPC).
Cohen D, Medina B, Du K, Coveler A, Manji G, Oberstein P, Perna S, Miller G. Phase II multi-institutional study of nivolumab (Nivo), cabiralizumab (Cabira), and stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer (LAUPC). Journal Of Clinical Oncology 2019, 37: tps4163-tps4163. DOI: 10.1200/jco.2019.37.15_suppl.tps4163.Peer-Reviewed Original ResearchStereotactic body radiotherapyImmune suppressionResection rateUnacceptable toxicityEfficacy of SBRTPhase II multi-institutional studySingle-arm phase II studyAdvanced unresectable pancreatic cancerArm phase II studyHigher R0 resection rateAdaptive immune suppressionImmune suppressive phenotypeM-CSFPD-1 blockadePhase II studyR0 resection rateStandard induction chemotherapyUnresectable pancreatic cancerSurgical resection rateAnti-tumor responseT cell populationsEfficacy of RTPlacement of fiducialsPre-clinical modelsMulti-institutional study
2018
Survival Outcomes and Prognostic Factors for Gastric Cancer in the Adjuvant Setting: An Analysis of the National Cancer Database
Nguy S, Wu P, Lee A, Tam M, Schreiber D, Du K. Survival Outcomes and Prognostic Factors for Gastric Cancer in the Adjuvant Setting: An Analysis of the National Cancer Database. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e49. DOI: 10.1016/j.ijrobp.2018.07.462.Peer-Reviewed Original ResearchFactors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis
Chadi SA, Malcomson L, Ensor J, Riley RD, Vaccaro CA, Rossi GL, Daniels IR, Smart NJ, Osborne ME, Beets GL, Maas M, Bitterman DS, Du K, Gollins S, Myint A, Smith FM, Saunders MP, Scott N, O'Dwyer ST, de Castro Araujo RO, Valadao M, Lopes A, Hsiao CW, Lai CL, Smith RK, Paulson EC, Appelt A, Jakobsen A, Wexner SD, Habr-Gama A, Julião G, Perez R, Renehan AG. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. The Lancet Gastroenterology & Hepatology 2018, 3: 825-836. PMID: 30318451, DOI: 10.1016/s2468-1253(18)30301-7.Peer-Reviewed Original ResearchConceptsClinical complete responseIndividual participant dataComplete responseLocal regrowthRectal cancerCumulative incidenceParticipant dataNeoadjuvant chemoradiotherapyHazard ratioSustained clinical complete responseProportion of patientsCenter heterogeneityRecent systematic reviewCox frailty modelStage cT1CT2 tumorsMajor surgeryPrimary outcomeTreatment characteristicsChemoradiotherapyLower riskPatientsStudy heterogeneitySystematic reviewNovel management strategiesInitial experience of combination nivolumab and local-regional treatment in patients with advanced hepatocellular carcinoma (HCC).
Gu P, Park J, Zhong J, Guo S, Hickey R, Aaltonen E, Horn J, Du K, Shanbhogue K, Megibow A, Xu R, Kyritsis I, Cohen D, Newman E, Miller G, Welling T. Initial experience of combination nivolumab and local-regional treatment in patients with advanced hepatocellular carcinoma (HCC). Journal Of Clinical Oncology 2018, 36: e16149-e16149. DOI: 10.1200/jco.2018.36.15_suppl.e16149.Peer-Reviewed Original ResearchA phase I/II multi-center study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) for patients with locally advanced esophageal squamous cell carcinoma (ESCC).
Giuroiu I, Ku G, Leichman L, Du K, Oh P, Levinson B, Iqbal S, Thomas C, Wu J. A phase I/II multi-center study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) for patients with locally advanced esophageal squamous cell carcinoma (ESCC). Journal Of Clinical Oncology 2018, 36: tps199-tps199. DOI: 10.1200/jco.2018.36.4_suppl.tps199.Peer-Reviewed Original ResearchEsophageal squamous cell carcinomaAdvanced esophageal squamous cell carcinomaPathologic complete responseOverall survivalClinical CRRadiation therapyMedian progression-free survivalPhase IEfficacy of nivolumabCarboplatin/paclitaxelOverall survival benefitProgression-free survivalKaplan-Meier curvesSquamous cell carcinomaMulti-center studyLast dosePrimary endpointUnacceptable toxicitySurvival benefitComplete responseMeier curvesAbscopal effectCell carcinomaExtensive tumorsEsophageal cancerDosimetric evaluation of magnetic resonance-generated synthetic CT for radiation treatment of rectal cancer
Wang H, Du K, Qu J, Chandarana H, Das IJ. Dosimetric evaluation of magnetic resonance-generated synthetic CT for radiation treatment of rectal cancer. PLOS ONE 2018, 13: e0190883. PMID: 29304105, PMCID: PMC5755922, DOI: 10.1371/journal.pone.0190883.Peer-Reviewed Original Research
2017
Development and Implementation of a Statistics Curriculum for Radiation Oncology Residents
Gorovets D, Wu P, Ahmed I, Cohen P, Ishaq O, Katz L, Oh P, Shaikh F, Tam M, Rawn E, Du K, Vega R. Development and Implementation of a Statistics Curriculum for Radiation Oncology Residents. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e124. DOI: 10.1016/j.ijrobp.2017.06.893.Peer-Reviewed Original ResearchPatient Positioning Accuracy in Stereotactic Radiosurgery With Mask Fixation and Cone Beam CT
Xu Y, Silverman J, Du K, Das I, Kondziolka D. Patient Positioning Accuracy in Stereotactic Radiosurgery With Mask Fixation and Cone Beam CT. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e740-e741. DOI: 10.1016/j.ijrobp.2017.06.2383.Peer-Reviewed Original ResearchBiomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer
Oh P, Du K. Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. Current Colorectal Cancer Reports 2017, 13: 276-283. DOI: 10.1007/s11888-017-0376-3.Peer-Reviewed Original ResearchAdvanced rectal cancerRectal cancerNeoadjuvant chemoradiationComplete responsePathologic complete responseStandard of careBowel functionNeoadjuvant therapyOverall survivalTumor responsePotential complicationsChemoradiationBiologic factorsTreatment correlatesCancerSurgeryRecent reportsCurrent literatureBiomarkersResponseComplicationsPatientsTherapyCare
2016
Food as medicine: A randomized controlled trial (RCT) of home delivered, medically tailored meals (HDMTM) on quality of life (QoL) in metastatic lung and non-colorectal GI cancer patients.
Ishaq O, Mailhot Vega R, Zullig L, Wassung A, Walters D, Berland N, Du K, Ahn J, Leichman C, Jill Cohen D, Gu P, Chachoua A, Leichman L, Pearl K, Schiff P. Food as medicine: A randomized controlled trial (RCT) of home delivered, medically tailored meals (HDMTM) on quality of life (QoL) in metastatic lung and non-colorectal GI cancer patients. Journal Of Clinical Oncology 2016, 34: 155-155. DOI: 10.1200/jco.2016.34.26_suppl.155.Peer-Reviewed Original ResearchGI cancer patientsCancer patientsMetastatic lungHealthcare utilizationNutritional interventionFinancial toxicityFACT-G questionnaireTrial of homeAdvanced-stage cancerMetastatic cancer patientsLower healthcare costsQuality of lifeKnowledge of nutritionEligible patientsMalnutrition incidenceLonger hospitalMalnourished patientsPrimary endpointPS 0Oral alimentationPatient's symptomsQOL improvementShorter survivalFirst RCTGI cancersUpdated Analysis of a Multi-Institutional Radiation Oncology Clerkship Curriculum: A Report From the Radiation Oncology Education Collaborative Study Group
Kauffmann G, Gunther J, Braunstein S, Hara W, Spektor A, Brower J, Stahl J, Rao Y, Vargo J, Ye J, Fields E, Thomas C, Du K, Kruser T, Jimenez R, Hirsch A, Currey A, Yechieli R, Mohindra P, Golden D. Updated Analysis of a Multi-Institutional Radiation Oncology Clerkship Curriculum: A Report From the Radiation Oncology Education Collaborative Study Group. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: e412. DOI: 10.1016/j.ijrobp.2016.06.1666.Peer-Reviewed Original ResearchInfluence of Neutrophil-Lymphocyte Ratio and Other Independent Factors Predicting Failure in Locally Advanced Esophageal Malignancies
Mathew M, Elahi N, Osipov A, Bitterman D, Talcott W, Tuli R, Du K, Thomas T. Influence of Neutrophil-Lymphocyte Ratio and Other Independent Factors Predicting Failure in Locally Advanced Esophageal Malignancies. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: e204. DOI: 10.1016/j.ijrobp.2016.06.1104.Peer-Reviewed Original Research